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Abstract
Introduction: Identification of new therapeutic agents for breast cancer (BC) requires preclinical models that
reproduce the molecular characteristics of their respective clinical tumors. In this work, we analyzed the genomic
and gene expression profiles of human BC xenografts and the corresponding patient tumors.
Methods: Eighteen BC xenografts were obtained by grafting tumor fragments from patients into Swiss nude mice.
Molecular characterization of patient tumors and xenografts was performed by DNA copy number analysis and
gene expression analysis using Affymetrix Microarrays.
Results: Comparison analysis showed that 14/18 pairs of tumors shared more than 56% of copy number
alterations (CNA). Unsupervised hierarchical clustering analysis showed that 16/18 pairs segregated together,
confirming the similarity between tumor pairs. Analysis of recurrent CNA changes between patient tumors and
xenografts showed losses in 176 chromosomal regions and gains in 202 chromosomal regions. Gene expression
profile analysis showed that less than 5% of genes had recurrent variations between patient tumors and their
respective xenografts; these genes largely corresponded to human stromal compartment genes. Finally, analysis of
different passages of the same tumor showed that sequential mouse-to-mouse tumor grafts did not affect
genomic rearrangements or gene expression profiles, suggesting genetic stability of these models over time.
Conclusions: This panel of human BC xenografts maintains the overall genomic and gene expression profile of the
corresponding patient tumors and remains stable throughout sequential in vivo generations. The observed
genomic profile and gene expression differences appear to be due to the loss of human stromal genes. These
xenografts, therefore, represent a validated model for preclinical investigation of new therapeutic agents.
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Introduction
Breast cancer (BC) is the most commonly diagnosed
cancer and remains the leading cause of worldwide can-
cer-related death in women [1]. A better understanding
of BC biology is essential in order to identify new tar-
geted therapies and tumors with molecular profiles that
will respond to the targeted treatment. Gene expression
profiling of invasive BC has defined three main tumor
subtypes with very specific features (Luminal, Basal,
human epidermal growth factor receptor 2 (HER2)) [2].
It is now common knowledge that the pathologic char-
acteristics, array comparative genomic hybridization
(aCGH) profiles, gene and miRNA expression profiles
and activated pathways are radically different among
these subtypes, supporting the view that BC is a disease
composed of very different and independent molecular
subgroups. These subtypes have also been shown to dif-
fer in terms of clinical presentation (that is, differences
in axillary lymph node involvement, local and regional
recurrence, metastatic patterns and overall prognosis),
and in their sensitivity to systemic treatment [3].
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Preclinical experimental models that reproduce the
heterogeneity of this disease have become a major chal-
lenge in order to investigate the biology of each BC sub-
type and evaluate new targeted therapies. Such models
are necessary to examine the treatment efficacy of
potential new therapies and some have already contribu-
ted to the development of new human therapeutics
[4,5]. However, most of the existing in vivo models used
for preclinical trials of anticancer drugs are based on a
limited number of cell lines previously isolated from
human tumors and selected by cell culture prior to
implantation in immunodeficient animals. These models
do not reproduce the architecture of the primary tumors
[6,7]. In contrast, tumor xenografts obtained by engraft-
ment of tumor samples transplanted directly into ani-
mals seems to be able to reduce the biologic distance
between the original patient tumor and the in vivo
model. We have previously published a paper describing
a large panel of BC xenografts that maintain the cell dif-
ferentiation, morphology, architecture, vasculature, per-
ipheral growth and some of the molecular features of
the original patient’s tumor [8].
However, new aberrations are expected to appear in
xenografted tumors because of the selection pressure
operated by the host animal, the loss of human stroma
and the intrinsic genetic instability of breast tumors.
To address these issues, we compared the genomic
(that is, aCGH) profiles and gene expression profiles of
BC xenografts with their corresponding primary tumors.
We then evaluated tumor stability in human BC xeno-
grafts transplanted serially over several years, by com-
paring their profiles at early and late in vivo generations.
Genomic analyses showed that BC xenografts reflect
the genomic profile of the patient’s tumors, with addi-
tional DNA gains and losses. Gene expression profile
analysis showed dynamic variations between tumor pairs
(xenograft and primary tumor), with recurrent changes
in the expression of a small group of stroma-related
genes.
These data suggest that BC xenografts maintain the
overall genetic profile of the original tumors, with addi-
tional changes that could be explained by adaptation of
tumor cells to the new host.
Materials and methods
Establishment of tumor xenografts
Tumor specimens were obtained from BC patients with
their informed consent. Tumor fragments were removed
during surgery, as previously described [8]. Briefly, fresh
tumor fragments were grafted subcutaneously into the
interscapular fat pad of female Swiss nude mice under
anesthesia. Mice were kept in pathogen-free animal
housing (Institut Curie) and received estrogen (8 μg/
mL) diluted in drinking water. Xenografts appeared at
the graft site two to eight months after grafting. They
were subsequently transplanted from mouse to mouse.
The experimental protocol and animal housing were in
accordance with institutional guidelines as proposed by
the French Ethics Committee (Agreement B75-05-18,
France).
Histology and immunohistochemistry
The morphology of patient tumor tissues was compared
with that of the corresponding xenografts by examining
paraffin-embedded sections according to standard proto-
cols [8]. Tumors were removed from mice and immedi-
ately fixed in 10% formaldehyde solution for
immunohistologic examination.
Immunostaining was performed according to pre-
viously published protocols [9]. Briefly, 4 μm tissue sec-
tions were prepared from a representative sample of the
tumor. After rehydration and antigen retrieval in citrate
buffer (10 mM, pH 6.1), tissue sections were stained for
estrogen receptor (ER), progesterone receptor (PR) and
ERBB2/neu (HER2). Staining was revealed with the Vec-
tastain Elite ABC peroxidase mouse Immunoglobulin G
kit (Vector, Burlingame, CA, USA) using diaminobenzi-
dine (Dako A/S, Glostrup, Denmark) as chromogen.
Positive nuclear staining for ER and PR was recorded
according to standardized guidelines. ER (clone 6F11; 1/
200; Novocastra, Rungis, France), PR (PR; clone 1A6; 1/
200; Novocastra) and ERBB2 (clone CB11; 1/1,000;
Novocastra) expression was evaluated. For ERBB2, only
membranous staining was evaluated, as previously
defined [10].
Array comparative genomic hybridization
Genomic DNA was extracted as previously published
[11]. Co-hybridization was performed between extracted
DNA (primary BC or corresponding xenograft) and nor-
mal DNA. Genome-wide resources of 3,261 or 5,244
fluorescence in situ hybridization-mapped sequenced
bacterial artificial chromosome (BAC) and P1-derived
artificial chromosome (PAC) clones were represented as
immobilized DNA targets on glass slides, allowing a
mean resolution of 0.5 Mb throughout the genome.
Each clone was spotted in quadruplicate on slides pre-
pared by Integragen™ (Evry, France). DNA samples,
each 1.5 μg, were digested with DpnII enzyme (Ozyme,
Saint-Quentin-en-Yvelines, France) and labeled with
random priming using a Bioprime DNA labeling kit
(Life Technologies, Villebon sur Yvette, France) with the
appropriate cyanine dye (Cy3 or Cy5; Perkin-Elmer,
Courtaboeuf, France). The control and test DNAs were
co-precipitated with Cot-1 DNA (Life Technologies, Vil-
lebon sur Yvette, France), denatured and re-suspended
in hybridization buffer. After 24 hours of hybridization,
slides were washed with sodium dodecyl sulfate buffer
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and saline citrate, dried and scanned with a GenePix
4000B scanner (Axon Instruments Inc., Union City, CA,
USA). Image analysis was performed with GenePix 5.1
software (Axon) [12]. Any BAC with less than two repli-
cates flagged for not meeting qualitative spot criteria
was excluded. Normalization was performed with the
MANOR algorithm [12]. Spots showing a low signal-to-
noise ratio or poor replicate consistency were discarded.
Status assignment (loss, normal, gain and amplification
of chromosome copy number) was performed by using
the GLAD algorithm [13].
Hierarchical clustering was performed on profiles
based on probe status. The group average was used as
the similarity measure and the Pearson algorithm was
used as the agglomerative method. Separation into
groups was proposed on the basis of the structure of the
dendrogram. Data visualization and computation of
clustering were performed according to the VAMP
(Vizualization and Analysis of Molecular Profiles) analy-
sis procedure [12]. Pearson’s correlation coefficient was
calculated on altered clones based on their clone status
(clone status, that is, GNL: gain, normal, loss). For ana-
lysis of GNL differences, chromosomal segments were
defined as genomic regions with a constant copy num-
ber for all samples.
RNA extraction
Prior to RNA extraction, a tissue section from the
tumor fragments was stained with hematoxylin and
eosin to evaluate tumor cellularity. All tumors analyzed
comprised more than 40% of tumor cells on the tissue
section. Total RNA was isolated from 15-65 mg of fro-
zen tissue using TRIzol reagent (Invitrogen, Cergy-Pon-
toise, France) according to the manufacturer’s
instructions. The RNA concentration was measured by
absorbance at 260 nm. The quality of each RNA sample
was determined on the Agilent 2100 bioanalyzer (Agi-
lent Technologies, Palo Alto, CA, USA. RNA was pro-
cessed on chips only when the following criteria were
met: RIN (a measurement of RNA quality) ≥ 7, (28S/
18S) ≥ 1.4, (260 nm/230 nm) ≥ 1.8, and (260 nm/280
nm) ≥ 1.8.
Gene expression analysis
Affymetrix HGU133 Plus 2.0
The concentration and integrity/purity of each RNA
sample were measured using RNA 6000 LabChip kit
(Agilent) and the Agilent 2100 bioanalyzer. The DNA
microarrays used in this study were the Human Genome
U133 Plus 2.0 array containing 54,675 probe sets (Affy-
metrix, Santa Clara, CA, USA). One hundred nanograms
of total RNA were amplified and labeled according to
the Affymetrix 3’IVT express protocol. Each batch of
targets included an MAQC A sample to control for
target preparation and hybridization. Targets were vali-
dated according to yield and size of RNA, usually
obtained at the Institut Curie molecular biology facility.
Targets were hybridized on human and mouse microar-
rays. Chips were washed and stained on a fluidic station
according to the manufacturer’s protocol and were
scanned using an Affymetrix GCS3000 scanner. Micro-
array quality control assessment was performed using
the R AffyPLM and SimpleAffy packages available from
the Bioconductor web site. Relative Log Expression,
Normalized Unscaled Standard Errors, scaling factor,
percentage of “present” calls, 3’/5’ ratio and average
background tests were applied to determine the quality
of each experiment. Chip pseudo-images were produced
to assess artifacts on arrays that failed to pass the pre-
vious quality control tests. Selected arrays were normal-
ized according to the GC-RMA normalization procedure
[14]. Raw data can be obtained from the Institut Curie
Microarray Database [15].
Statistical analysis
Quality control analysis
Thirty-two xenograft and primary tumor samples and
two universal RNA were hybridized. Twenty-eight of the
32 gene expression microarrays were deemed to be of
sufficient quality. Considering that an expression signal
below a cut-off of 3.5 after GC-RMA normalization can-
not be distinguished from noise or missing signal, the
present analysis was based exclusively on probe sets
with a signal level less than 3.5 in no more than 85% of
the samples analyzed: 29,683 out of 54,675 probe sets
were included in the analysis.
Molecular subtype classification
Hu et al. defined and validated the centroids of 306
genes to discriminate between five previously identified
BC molecular subtypes (Luminal A and B, Basal, HER2
positive, Normal) [16]. The UniGene ID (Build204) gene
list was matched to the HG-U133 Plus 2.0 Affymetrix©
platform annotation. Each sample was assigned to the
nearest subtype/centroid as determined by the highest
Spearman rank order correlation between the gene
expression values of the molecular subtype probe sets
and the five subtype centroids. A sample with a maxi-
mum correlation score less than 0.2 was considered to
be unclassified.
Differential expression analysis
The gene expression profiles of the pairs (xenograft and
corresponding primary tumor; xenograft at different
tumor passages) were assumed to be similar (null
hypothesis). The scatter plots of the whole gene expres-
sion data set for pairs of xenografts and corresponding
primary tumors and pairs of xenografts from different
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passages confirmed this hypothesis. A linear regression
model was fitted to analyze the variation in gene expres-
sion of each pair (xenograft and corresponding primary
tumor or xenograft after several generations). Linear
regression models were built to define the 5th and 95th
percentiles of the residual distribution. Normality testing
was limited to observation of the density plot and a
quantile-quantile plot of the residual values. A residual
above the 95th percentile or below the 5th percentile
was considered to be an outlier.
Gene ontology analysis
This analysis was performed to determine whether spe-
cific gene sets (that is, functional groups) were overre-
presented in the various gene lists. The DAVID
(Database for Annotation, Visualization and Integrated
Discovery) Gene Ontology web site was used to test the
significance of enrichment in specific gene ontology
annotations [17].
Results
Histologic and immunohistochemical analysis of tumors
A preliminary histologic analysis of xenografts com-
pared their morphology and pathological classification
(based on HER2, ER and PR receptor expression) with
those of the primary tumors. Results based on immu-
nohistochemistry data are summarized in Table 1 and
have been previously published in part [8,18]. Figure 1
illustrates the histology of patient- and xenograft-
derived tumors for each of the following BC subtypes:
luminal human breast cancer xenograft (HBCx-3), tri-
ple-negative (HBCx-8, HBCx-12A and HBCx-10),
HER2+ (HBCx-5), and lobular (HBCx-19). The primary
HBC-3 BC was an infiltrating ductal adenocarcinoma
organized in cell cords with a small in situ component.
The xenografted tumors showed a similar architecture
with an abundant stromal component. The triple-nega-
tive HBCx-8 and HBCx-10 tumors were diagnosed as
infiltrating ductal carcinoma with a trabecular architec-
ture that was reproduced in the xenograft. The HBCx-
12A was a poorly differentiated ductal carcinoma with
a large number of mitotic figures and large cells with
abundant cytoplasm. Images at a magnification of 2.5
× of the patient’s luminal HBCx-3 and HER2+ HBCx-5
tumors showed a high content of stromal component
(Figure 1A, D). Organization of stroma around the
tumor cell nests in HER2+ tumors was reproduced in
the xenograft.
Array CGH analysis of xenografts and corresponding
patient tumors
To evaluate the similarity of genomic profiles between
the tumors and their corresponding xenografts, a BAC
aCGH analysis was performed on 18 pairs, of which 2
were HER2+, 4 were ER positive and 12 were triple-
negative (Table 1).
Copy number alterations (CNA) of each pair of
patient tumors and xenografts were compared by calcu-
lating Pearson’s correlation coefficients R. Fourteen
pairs had a correlation coefficient greater than 0.50,
indicating similarity (Table 1). The correlation coeffi-
cient was less than 0.5 in four pairs: one pair was HER2
+ and three were triple-negative. No correlation with
the percentage of high quality clones analyzed was iden-
tified (data not shown).
Two examples of paired aCGH profiles are shown in
Figure 2. In Figure 2A, both the primary ER positive
tumor and the xenograft displayed a slightly altered
profile. Most of the alterations were conserved in the
xenografts, such as the 1q gain, Xp22 amplification, 2q
loss, and alterations in 14p, 15q, and 17. A gain in the
11p region was observed in the xenograft but not in
the original tumor. Profiles of the triple-negative
tumors are shown in Figure 2B. Most of the chromo-
somes were affected by genomic alterations. Large
genomic gains were observed in almost all chromo-
somes. Three large genomic losses, in chromosomes 3,
Table 1 Histopathologic features of breast cancer
xenografts and genomic correlation between primary
tumor and xenograft
Tumor
xenograft
Phenotype (IHC)
Patient/xenograft
Histology Pearson’s
correlation
coefficient
HBCx-3 ER+/ER+ IDC 0.76
HBCx-5 HER2+/HER2+ IDC 0.35
HBCx-6 TN/TN IDC 0.60
HBCx-7 TN/TN ILC 0.23
HBCx-8 TN/TN IDC 0.82
HBCx-10 TN/TN IDC 0.57
HBCx-11 TN/TN IDC 0.65
HBCx-12A TN/TN IDC 0.66
HBCx-13A HER2+/HER2+ IDC 0.86
HBCx-15 TN/TN IDC 0.57
HBCx-16 TN/TN IDC 0.46
HBCx-17 TN/TN IDC 0.39
HBCx-20 ER+/ER+ IDC 0.87
HBCx-21 ER+PR+/ER+PR+ IDC 0.86
HBCx-22 ER+ PR+/ER+PR+ IDC 0.68
HBCx-23 TN/TN IDC 0.80
HBCx-24 TN/TN IDC 0.77
HBCx-31 TN/TN IDC 0.86
ER, estrogen receptor; HBC, human breast cancer; HBC-n, HBC primary tumor
n; HBCx-n, HBC xenograft tumor n; HER, human epidermal growth factor
receptor; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; ILC;
invasive lobular carcinoma; PR, progesterone receptor; TN, triple-negative. List
of xenografts used in the study according to the breast cancer subtype.
Expression of HER2; ER and PR was determined by IHC. Pearson’s correlation
coefficients between pairs of patient tumors and xenografts were calculated
between the clone status (Gain, Normal, Loss) of the same probe.
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13 and X, were conserved in the xenograft. Slight
amplifications of genomic alterations were observed in
the xenograft profile, for example, in chromosomes 1,
6, 7 and 17. Non-altered regions were fairly similar in
both profiles.
Clustering of aCGH data set
Unsupervised hierarchical clustering analysis of CNA
was performed on the whole sample set (18 pairs of pri-
mary tumors and corresponding xenografts) in order to
determine whether tumors and xenografts were clonally
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Figure 1 Histology and IHC analysis of primary tumors and xenografts. Representative hematoxylin-eosin or hematoxylin-eosin-saffron
stained sections of patient tumors and xenografts. A, luminal tumor HBC(x)-3. B, lobular tumor HBCx-19. C, triple-negative tumor HBC(x)-12A. D,
HER2+ tumor HBCx-5. E, triple-negative tumor HBC(x)-10. F, triple-negative tumor HBC(x)-8. HBC, human breast cancer, HBC-n, HBC primary
tumor n, HBCx-n, HBC xenograft tumor n, HER2+, human epidermal growth factor receptor 2 positive, IHC, immunohistochemistry.
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related (Figure 3A). Sixteen of the 18 patient-xenograft
pairs clustered together, indicating greater differences in
CNA between primary tumors than between a primary
tumor and its corresponding xenograft. Luminal and
HER2+ BC subtypes clustered into two separate sub-
groups that were distinct from the triple-negative sub-
group. In two cases, xenografts derived from the
primary tumor and axillary lymph node from the same
patient (HBCx-12A/B and HBCx-13A/B) clustered clo-
sely with the corresponding primary tumors (Figure 3B).
This result highlights the fact that no major differences
in CNA were observed between xenografts derived from
breast tumors or the corresponding axillary node metas-
tases. In addition, the two HBCx-12A/12B and HBCx-
13A/13B pairs clustered into two small subclusters, indi-
cating a higher degree of similarity between xenografts
derived from primary tumors and metastases than
between patient tumors and xenografts. An example of
the similarity between primary tumor-derived xenografts
and metastasis-derived xenografts is shown in Figure
4A. The Pearson correlation coefficients between the
patient tumor and the corresponding xenograft were
0.86 and 0.82 (for a primary tumor-derived xenograft
and a metastasis-derived xenograft, respectively). A very
A
B
HBC-21 patient
HBCx-21 xenograft
HBCx-31 xenograft
HBC-31 patient
Figure 2 Array CGH profiles of patient tumors (top) and xenografts (bottom) compared with normal DNA. Recurrence of copy number
alterations is plotted on the y-axis and each probe is aligned along the x-axis in chromosomal order. Loss, gain or amplification of gene copy
numbers are depicted in green, red and blue, respectively. A, array CGH profile of a luminal tumor. B, array CGH profile of a triple-negative
tumor. CGH, comparative genomic hybridization, HBC, human breast cancer, HBC-n, HBC primary tumor n, HBCx-n, HBC xenograft tumor n.
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strong correlation was also observed between the two
xenografts, with a correlation coefficient of 0.85. Impor-
tantly, the HER2 amplicon, localized on chromosome
17q21-22, was preserved in both the primary tumor-
derived xenograft and the metastasis-derived xenograft
(Figure 4B). A second amplicon, frequently associated
with HER2 amplicons, localized on chromosome 8
(8p12-p11), was also found in the three genetic profiles.
To study the stability of xenografts in serial transplan-
tation, the genetic profile of four xenografts was ana-
lyzed from different passages and compared to the
profile of the original patient tumor. The genomic pro-
files of xenografts remained very stable throughout
sequential in vivo passages. An example of aCGH pro-
files at different passages is shown in Figure 4C; the
HBCx-21 profiles at p1 and p6 (30 months later),
demonstrate a strong homology between the two
tumors.
Analysis of recurrent alterations observed in patient
tumors and xenografts
CNA frequency plots were analyzed for differences
between patient tumors and xenografts (Figure 5A). The
patient tumor plot showed highly rearranged profiles,
reflecting the intrinsic genetic instability of BCs. This
general CNA frequency pattern was reproduced in the
xenograft plot with additional alterations observed for
several chromosomes. To analyze the chromosomal
regions that differed between xenografts and patient
tumors, a “GNL difference” was calculated for each
chromosomal segment: a segment was defined as a
region with a constant copy number for all samples.
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Figure 3 Clustering of array CGH data set. The length of each horizontal dendrogram arm indicates the degree of correlation between the
various specimens, ranging from 0% to 100% correlation. The shorter the dendrogram arm, the greater the degree of correlation. A,
unsupervised hierarchical clustering analysis of copy number alterations on the whole sample set (18 pairs of primary tumors and corresponding
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comparative genomic hybridization, HBC, human breast cancer, HBC-n, HBC primary tumor n, HBCx-n, HBC xenograft tumor n, HER2+, human
epidermal growth factor receptor 2 positive. Red, luminal tumors; black, triple-negative tumors; green, HER2+ tumors.
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The 1,351 segments analyzed are listed in Additional file
1, Table s1 and the frequency distributions of neutral,
positive and negative GNL differences are shown in Fig-
ure 5B. A positive GNL difference indicates an increased
copy number in the xenograft versus the patient tumor,
while a negative GNL difference indicates a decreased
copy number. Differences were calculated for 20 pairs
corresponding to 18 patients and 20 xenografts (xeno-
grafts were generated from the primary tumor and, in
addition, from a metastasis in two patients) and regions
present in at least 10 comparisons were analyzed. The
chromosomal distribution of these differences (corre-
sponding to 992 segments) is illustrated in Figure 5C.
The analysis was restricted to chromosomal segments
showing negative or positive GNL differences in at least
30% of pairs (and present in at least 10 comparisons) in
order to identify recurrent changes. It showed that 178
regions were lost and 202 regions were gained (Addi-
tional file 1, Table s2 and Table s3, respectively). The
chromosomal distribution of these recurrent changes
(Figure 5D) shows that gains mainly involved chr 1 and
chr 17 (35% and 17%, respectively), while CNA losses
occurred in chr 1, chr 5, chr 12 and chr 18 (23%, 19%,
16%, respectively). The chromosomal regions involved
in recurrent gains and losses are shown in Table 2.
Some regions (chromosomes 1p, 15q, 16p, 18p) were
involved in both gains and losses, while other regions
were mainly associated with either gains or losses.
Molecular subtype classification
The molecular classification of patient tumors and xeno-
grafts was determined using 306 genes that allow for
discrimination between the five BC molecular subtypes
(Luminal A and B, Basal, HER2, Normal); these genes
HBC-21patient
HBCx-21 p1 xenograft
HBCx-21 p6 xenograft
A
C
HBC-13 patient
HBC-13A primary tumor xenograft 
HBC-13B metastasis tumor xenograft 
Chr 17Chr 8
BB
Figure 4 Stability of CGH profiles between primary and metastasis profiles and throughout successive xenograft generations. A, aCGH
profile of the HBCx-13 tumors derived from a patient’s primary breast tumor (upper), breast tumor-derived xenograft (middle), and axillary
metastasis-derived xenograft (bottom). B, details of the aCGH profile of chromosome 17 amplicon (containing the HER2 oncogene amplification
and chromosome 8 amplicon. C, aCGH profiles of the luminal HBC-21 patient tumor and xenografts from different in vivo tumor passages (p6
corresponding to a time lapse of 30 months after the first tumor engraftment). aCGH, array comparative genomic hybridization; HBC, human
breast cancer; HBC-n, HBC primary tumor n; HBCx-n, HBC xenograft tumor n; HER2, human epidermal growth factor receptor 2.
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were defined and validated by Hu et al. [16]. Matching
the UniGene ID (Build204) gene list to the HG-U133
Plus 2.0 Affymetrix© platform annotation identified a
total of 296 (729 probe sets) of the 306 genes. In a
group of 28 tumors (including 10 patient tumors and 18
xenograft tumors at various later generations in vivo),
12 samples were classified as Basal, 6 as Luminal A, 3 as
Luminal B and 2 as Normal (Table 3). Spearman corre-
lation coefficients were less than 0.20 for seven of these
tumors and the corresponding samples were conse-
quently considered “unclassified”. In 6 of the 10 com-
parisons, the molecular signature was concordant and in
two cases the patient’s tumor was classified as Normal
and the xenograft was classified as Basal.
Gene expression analysis
Linear regression analysis was performed to study the
global gene expression pattern in xenografts versus pri-
mary tumors. An example of the correlation between
gene expression patterns is shown in Figure 6. Probe
sets that were not differentially expressed fitted a linear
model (black dots), while red dots represent extreme
residual values (overexpressed or under-expressed). The
gene expression scatter plot between the patient tumor
and the xenograft indicates that the great majority of
probes were not differentially expressed (Figure 6A).
Linear regression analysis performed of xenografts from
different tumor passage (passage 3 versus passage 6)
showed very few probe sets with differential expression
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Figure 5 Representation of differences in CNA between patient tumors and xenografts. A, frequencies of genome copy number gains
and losses plotted as a function of genome location in the patient tumors (left) and xenografts (right). Frequencies are based on GNL status and
colors are calculated from the proportions of profiles without missing values. B, Frequency distributions plots of unchanged, positive and
negative GNL differences. C, Frequency of CNA alterations distributed along chromosomes. Frequencies were calculated as the difference
between patient tumor and xenograft GNLs. Negative frequencies represent DNA losses, while positive frequencies represent gains in xenografts.
Only segments present in 10 or more pairs are shown (n = 992). D, Distribution of recurrent CNA gains (lower figure) and losses (upper figure)
along chromosomes (frequency calculated for GNL differences occurring in at least 30% of pairs, n = 202 and 176, respectively). CAN, copy
number alteration; FrAGL, Frequency of Amplicon, Gain and Loss; GNL, gain, normal, loss.
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(Figure 6B), indicating that gene expression did not
undergo any major changes during the course of
mouse-to-mouse grafts. Analysis of all paired samples
(primary tumor vs corresponding xenograft) showed a
significant decrease in the number of probe sets differ-
entially expressed exclusively in one pair (5,530 out of
29,683; 18.6%) or common to 13 pairs (225 out of
29,684; 0.7%). A similar, significant trend was observed
for the proportion of overexpressed versus under-
expressed genes (Chi-square test, P = 1e-16) with a
decreasing number of overexpressed genes when com-
paring the list of probe sets exclusive to one pair (3,114
out of 5,530; 56.3%) to the list of probe sets common to
13 pairs (6 out of 225; 2.6%) (Figure 6C). Gene Ontology
analysis was performed on four probe set lists, that is,
common to 1 to 3 pairs, 4 to 6 pairs, 7 to 9 pairs and
10 to 13 pairs (Additional File 2, Tables S1, S2, S3 and
S4). A significant enrichment in annotations corre-
sponding to the immune system, response to external
stimuli, response to wounding, cell adhesion, inflamma-
tory response, blood vessel formation, skeletal develop-
ment and cell motility was observed in the group of
probe sets common to 10 to 13 pairs (Table 4 and
Additional file 3, Table S1). The group common to one
to three pairs was mainly enriched in annotations corre-
sponding to protein transport, messenger RNA proces-
sing, RNA splicing, cell adhesion, regulation of cell
proliferation, regulation of cell death and apoptosis, but
no annotation related to the immune system was identi-
fied. Analysis of these ontology annotations in the four
groups showed an interesting pattern. Significant anno-
tations in the first group progressively became non-sig-
nificant in the second and third groups and, inversely,
significant annotations in the fourth group progressively
became non-significant.
For instance, gene expression analysis performed on
xenografts after multiple passages identified only 11
probe sets (0.03%) differentially expressed in more than
50% of the paired samples (data not shown).
Altogether, these data show that xenografts display a
relatively similar gene expression profile compared with
their corresponding human tumors.
Discussion
The aim of the present study was to analyze the mole-
cular profiles of a panel of human BC xenografts
directly transplanted from patient tumor samples.
Tumors transplanted into a host animal are subject to
Table 2 Chromosomal regions with DNA copy number
differences between patient tumors and xenografts
Gain Loss
1p22-36 1p12-36
2p16 1q21-q34
2p21-p24 2p11-q11
5p15 4p16
7q22 5q11-q31
9q34 9p23-24
10p15 9q13-32
11p13 11p15
11q12-q14 11q22
13q13 12p11-p13
13q33-q34 12q21
14q11 15q24-q26
15q22-q25 16p13
16p13 17p11-13
17p11-q11 17q23-q24
18p11 18p11
19q13 18q12-q22
20q11 19p11-p12
22q12-q13 19q22
Table 3 Molecular subtype classification of primary
tumors and corresponding xenografts at later
generations
Tumor code Origin Molecular subtype
HBC(x)-3 patient LumA
xenograft p2 LumB
xenograft p6 LumA
HBC(x)-5 patient LumA
xenograft p2 LumB
xenograft p5 LumB
HBC(x)-6 patient Basal
xenograft p0 Basal
xenograft p6 Unclassified
HBC(x)-7 patient Unclassified
xenograft p7 Unclassified
xenograft p9 Unclassified
HBC(x)-10 xenograft p4 Basal
xenograft p8 Basal
patient Basal
HBC(x)-13 patient LumA
xenograft p6 Unclassified
HBC(x)-15 patient Normal
xenograft p1 Basal
xenograft p5 Basal
HBC(x)-12A patient (primary tumor) Normal
xenograft (primary) p8 Unclassified
xenograft (primary) p5 Basal
HBC(x)-12B patient (metastasis) Unclassified
xenograft (meta) p3 Basal
xenograft (meta) p6 Basal
HBC(x)-19 patient LumA
xenograft LumA
HBC, human breast cancer; HBC-n, HBC primary tumor n; HBCx-n, HBC
xenograft tumor; LumA, luminal A; LumB, luminal B; meta, metastasis; P,
passage
Reyal et al. Breast Cancer Research 2012, 14:R11
http://breast-cancer-research.com/content/14/1/R11
Page 10 of 14
HBCx-12B xenograft P3
H
B
C
x
-1
2
B
 x
en
o
g
ra
ft
 P
6
HBCx-12B xenograft P3
H
B
C
-1
2
B
  
p
a
ti
en
t
CA B
Number of pairs
Figure 6 Gene expression analysis by Affymetrix GeneChip probe arrays. A, Variation of gene expression between the primary HBC-12B
tumor and the corresponding xenograft. Scatter plot representing the gene expression of 29,683 probe sets (primary tumor versus xenograft
p3). red dot, probe sets with high residual values. B, Variation of gene expression between xenograft at passage 3 and passage 6. C, Number of
overexpressed (red) and underexpressed (green) genes between patient tumor/xenograft pairs HBC, human breast cancer; HBC-n, HBC primary
tumor n; HBCx-n, HBC xenograft tumor n.
Table 4 David Enriched Gene Ontology Categories in Genes Expressed Differently between patient tumors and
xenografts
Gene Ontology Biologic Process Count % List Total Fold Enrichment Benjamini
immune response 98 16.2 479 4.01 8.12E-30
cell adhesion 94 15.6 479 3.79 9.26E-27
biologic adhesion 94 15.6 479 3.79 6.90E-27
response to wounding 80 13.2 479 4.26 7.08E-26
defense response 72 11.9 479 3.31 1.51E-16
inflammatory response 49 8.1 479 4.26 7.35E-15
blood vessel development 41 6.8 479 4.73 1.62E-13
vasculature development 41 6.8 479 4.61 2.48E-13
extracellular matrix organization 26 4.3 479 7.06 4.28E-12
positive regulation of immune system process 35 5.8 479 4.15 8.12E-10
extracellular structure organization 28 4.6 479 4.85 4.15E-09
wound healing 30 5.0 479 4.44 6.13E-09
blood vessel morphogenesis 31 5.1 479 4.15 1.38E-08
positive regulation of response to stimuli 32 5.3 479 3.83 4.73E-08
regulation of response to external stimulus 26 4.3 479 4.62 5.46E-08
taxis 26 4.3 479 4.59 5.87E-08
chemotaxis 26 4.3 479 4.59 5.87E-08
angiogenesis 25 4.1 479 4.77 5.70E-08
regulation of cell activation 27 4.5 479 4.36 7.17E-08
regulation of cell migration 26 4.3 479 4.34 1.61E-07
skeletal system development 36 6.0 479 3.19 3.25E-07
regulation of locomotion 27 4.5 479 3.97 4.70E-07
regulation of cell motion 27 4.5 479 3.95 5.01E-07
regulation of T cell activation 21 3.5 479 5.07 4.87E-07
Enriched Gene Ontology Categories in Genes Expressed Differently between patient tumors and xenografts and common to 10 to 13 pairs (first 25 categories
represented). BP, biologic process
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different stroma and selection pressures, which can
impact on the tumor’s molecular profile. We, there-
fore, compared the genomic and gene expression pro-
files of BC xenografts with their corresponding patient
tumors. As illustrated by histologic and immunohisto-
chemical examinations, and as previously reported,
these xenografts maintained the biologic markers of
the patient’s primary tumors as well as their micro-
scopic morphology [8].
Characterization and comparison of CNA and cluster-
ing analysis showed that the original genetic profile was
generally maintained in the xenograft. Accurate quantifi-
cation of homology is a complex procedure, as breast
carcinomas display intratumor heterogeneity [19,20] and
xenografts are obtained by selecting only a small frag-
ment of the tumor sample after surgery. The correlation
between CNA profiles of pairs of xenografts and pri-
mary tumors was noteworthy, being greater than 0.5 for
most of the paired samples (16/18). The similarity
between genomic profiles appeared to be greater for tri-
ple-negative and luminal tumors than for HER2+
tumors, which could be explained by the fact that Her2
positive tumors are less markedly altered and are com-
posed largely of stromal cells (see Figure 1), leading to
underestimation of the correlation coefficient calculated
on tumor DNA alterations. Analysis of the genomic pro-
files showed that the majority of tumors had a concor-
dant distribution of chromosomal gains and losses, and
maintained amplification regions. However, an enrich-
ment of genomic rearrangements was observed in the
xenografts, as previously demonstrated by our team, as
well as by other authors [8,21-23].
Analysis of recurrent changes observed in xenografts
showed enrichment of CNA in certain chromosomes.
The majority of these regions are known to be asso-
ciated with chromosomal imbalances in BC cells derived
from either tumor samples or cell lines. In the present
analysis, negative differences corresponded to deletions
that were not detected in the patient tumor or DNA
gains that were lost in the xenograft. Conversely, posi-
tive values represented gains observed in xenografts that
were not detected in the patient tumor or deletions pre-
sent in the patient tumor but lost in the xenograft. The
greater number of DNA rearrangements observed in the
xenografts compared to the patient tumors (Figure 5A)
suggests that the CNA differences observed were due to
gains or losses occurring in xenografts and not present
in the patient tumors, rather than losses and gains in
the patient tumors that returned to a normal status in
the xenograft. In addition, the majority of regions pre-
senting high frequencies of CNA changes were
associated with chromosomal imbalances in BC. This
result is concordant with those of a recent paper that
analyzed the chromosomal aberrations in a panel of
nine patient-derived models of sarcoma. Kresse et al.
showed that many CNA changes found in xenografts are
frequently observed in sarcoma patients, suggesting that
xenografts may in some way represent the genomic rear-
rangement intrinsic to tumor progression [23]. In the
case of breast cancer, Ding et al. studied the pattern of
genetic differences between a patient’s tumor and the
corresponding xenograft. Although their conclusions are
based on analysis of a single patient’s tumor, this study
elegantly demonstrated that many of the mutations
detected in the xenograft were also observed in brain
metastases derived from the same patient [24]. The fact
that genomic alterations are conserved for several years,
without any major changes, as demonstrated by sequen-
tial CGH analysis after multiple passages in vivo, suggests
that genomic profiles remain relatively stable over time
despite new selection pressures and loss of human
stroma. This finding was also demonstrated by clustering
analysis, in which the similarity between different xeno-
graft passages was greater than the similarity between the
xenograft and the original tumor, indicating that selec-
tion of breast tumor cells at the time of the first tumor
engraftment is the major source of genetic variability.
This observation can be explained by a selective tumor
cell process during in vivo transplantation. In addition,
loss of the human stromal compartment in xenografts
results in enrichment of human tumor cells, and conse-
quently enrichment of DNA alterations not detected in
the patient’s tumor.
The amplifications present in the patient’s tumors
were generally conserved in the xenografts, except for
the HBC-8 tumor, in which the changes were limited to
DNA gains. This suggests that these genomic regions do
not undergo any major variations after grafting tumors
into immunocompromised mice. More than 40 (42)
amplicons were detected in the panel of BC xenografts
(8p11.2-p12, 8q24, 11q13.3, 17q12-q21 and 20q13.3).
Several of them have been frequently described in BC
patients and carry potential oncogenes, the overexpres-
sion of which may be important for initiating, survival
and/or development of breast tumors [25,26].
In terms of gene expression, less than 20% of probe sets
showed significant variations on a single comparison and
these genes were not enriched in stroma-related compo-
nents. Investigation of genes with recurrent changes
(common to 10 to 13 pairs) identified a small group of
205 genes associated with stromal gene ontology annota-
tions, consistent with changes in the tumor environment
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from human to mouse. Another study compared gene
expression between two BC xenografts and patient
tumors [21]. Bergamaschi et al. reported a significant var-
iation in the expression of human extracellular matrix-
related genes that were down-regulated in xenografts
compared with primary tumors. Interestingly, we also
found that about one-half of the genes that were down-
regulated in xenografts were correlated with breast carci-
noma prognosis (data not shown). This set of genes is
enriched in the immune system and is composed of
immune response-related genes. Inversely, the set of
genes not correlated with prognosis was highly enriched
in wound response, cell adhesion, blood vessel develop-
ment, extracellular matrix organization and cell migra-
tion related genes. These results indirectly emphasize the
major role of the stromal compartment and the immune
system in the prognosis of breast carcinoma [27].
The gene expression profile data may provide impor-
tant information on pathway activation or cellular tar-
gets for novel anticancer agents, and it may also
contribute to the identification of genes affecting
response to treatment. Additional gene expression stu-
dies and pathway signaling analyses will be necessary to
complete the molecular characterization of BC xeno-
grafts, especially in the context of preclinical develop-
ment of molecular targeted agents.
Conclusions
In conclusion, this panel of human BC xenografts, main-
tained by grafting fresh fragments through sequential
passages, demonstrates that xenograft breast tumors
reflect the general genetic profile of the patients’ tumors.
The genomic and gene expression profile differences
observed were consistent with the high grade of genetic
instability of BC, and loss of the human stromal compo-
nent. In addition, studying tumors after various passages
in vivo showed that these models conserve a high degree
of genomic and gene expression stability over time.
These analyses support the use of the primary BC
xenografts as preclinical models to study the effect of
new anticancer drugs and to identify biologic factors
associated with drug response.
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